Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2016 · The Lancet · 3,590 citations
https://doi.org/10.1016/s0140-6736(16)32453-9
P
Paul J. Ross
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
396
Papers
23.6K
Citations
61
h-index
151
i10-index
Paul J. Ross is an academic researcher from King's College Hospital NHS Foundation Trust. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Colorectal Cancer Treatments and Studies & Renal cell carcinoma treatment. The author has an h-index of 61, co-authored 337 publications.
ORCID: 0000-0002-2390-1886Papers by this author
worksCapecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
2019 · The Lancet Oncology · 1,180 citations
https://doi.org/10.1016/s1470-2045(18)30915-x
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
2019 · The Lancet Oncology · 1,180 citations
https://doi.org/10.1016/s1470-2045(18)30915-x
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
2021 · The Lancet Oncology · 711 citations
https://doi.org/10.1016/s1470-2045(21)00027-9
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
2004 · British Journal of Cancer · 470 citations
https://doi.org/10.1038/sj.bjc.6601781
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
2015 · The Lancet Oncology · 276 citations
https://doi.org/10.1016/s1470-2045(15)00139-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat